Nomination Committee’s proposal for election of Board members and auditor of Boule Diagnostics AB
The Nomination Committee of Boule Diagnostics AB has decided to propose to the Annual General Meeting 2021 (AGM) that the number of Board members shall be seven including the Chairman. The Nomination Committee proposes the re-election of Peter Ehrenheim as the Chairman of the Board and the re-election of Jon Risfelt, Thomas Eklund, Karin Dahllöf and Charlotta Falvin as Board members. Furthermore, the Nomination Committee proposes that the AGM elects Yvonne Mårtensson and Torben Jørgensen as new Board members.
Has successfully, in her role as CEO, taken CellaVision AB from a “start-up” to a global and fast-growing listed company. Yvonne has extensive experience from leading positions in international sales and marketing, primarily in medical equipment and diagnostics. Current board assignments include Chairman of the Board of Elos Medtech and Board member of XVIVO Perfusion and Lyfstone A/S.
Torben has extensive operational experience in the diagnostics and medtech sector, including being the President and CEO of Biotage between 2006–2019, Affibody AB 2001–2005, Karo Bio 2000–2001 and in the Danish diagnostics company DAKO A/S 1990–2000. Torben has been a central part of Biotage’s successful international expansion during his time as CEO. Current board assignments include Chairman of the Board of Biotage, Genovis and Atlas Antibodies AB as well as Board member of Micropos Medical and Advanced Instruments.
The Nomination Committee proposes that the recognized auditing firm Öhrlings PricewaterhouseCoopers AB (PwC) is re-elected as the Company’s auditor for the coming financial year. The proposal is in agreement with the recommendation made by the Board (the Audit Committee). PwC has announced that they, if they are appointed, will propose the Authorized Public Accountant Lars Kylberg to be the new auditor in charge.
The Nomination Committee’s proposals to the AGM 2021 in full will be disclosed together with the notice convening the Annual General Meeting as it is issued at the latest.
For further information, please contact:
Ulf Hedlundh, Chairman of the Nomination Committee, Boule Diagnostics AB, firstname.lastname@example.org, phone +46 (0)8-440 37 70
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46 (0)70-546 72 22
About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com
The information was submitted for publication, through the agency of the contact person set out above at 17:00 CET on March 3, 2021.